Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |
mRNA | CAY10594 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.7 |
mRNA | BRD-K33514849 | CTRPv2 | pan-cancer | AAC | -0.052 | 0.7 |
mRNA | Axitinib | FIMM | pan-cancer | AAC | -0.074 | 0.7 |
mRNA | QW-BI-011 | CTRPv2 | pan-cancer | AAC | -0.033 | 0.7 |
mRNA | LE-135 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |
mRNA | BRD-A94377914 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.7 |
mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.02 | 0.7 |
mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.015 | 0.7 |
mRNA | blebbistatin | CTRPv2 | pan-cancer | AAC | 0.035 | 0.7 |